GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2009

FAB Pharma Raises $3.36M for MRSA Drug Development

  • FAB Pharma completed a €2.3 million (about $3.36 million) Series A fundraising round. Proceeds will be used in the ongoing Phase I development of anti-MRSA candidate Fab-001 and for back-up products.

    The financing round was co-led by CDC Innovation and Bioam Gestion. The US healthcare-focused hedge fund Redmile Group also contributed to the financing.

    FAB Pharma, a spin-out from French antibacterials company Mutabilis, has a small molecule anti-MRSA program based on candidates like Fab-001 that target the essential MRSA enzyme, fatty acid biosynthesis I (FAB I).

    FAB Pharma claims that Fab-001 has a completely different mechanism of action to any other drug on the market or in late-stage development. Recruitment for the Phase I study of the drug (a single-dose injection in healthy volunteers) has just begun and the study should be completed by the end of this year. A second Phase I trial with multiple-ascending doses may start later this year.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Global Antibiotic Resistance

Do you find the association of a country’s antibiotic resistance being tied to its degree of corruption rather than its wealth surprising?

More »